Treating malignant pleural effusions cost consciously

Chest
C P BelaniC L Bennett

Abstract

Malignant pleural effusions are associated with significant morbidity. Prompt clinical evaluation followed by aggressive treatment often results in successful palliation. This report summarizes the traditional and experimental approaches used in the management of malignant pleural effusion and provides an attempt at analysis of cost comparison and resource utilization associated with the use of various sclerosing agents. The standard sclerotherapy for malignant pleural effusions has routinely been performed as an inpatient procedure using a large-bore chest tube for drainage and instillation of a sclerosing agent. Use of a small-bore catheter for drainage and pleurodesis is associated with reduced patient discomfort and appears to be feasible and equally efficacious in the ambulatory setting. Results with the ambulatory procedure are preliminary but promising. Future comparisons with the traditional approach will allow therapy to be based not only on efficacy, but also on the use and expense of related resources.

References

Nov 8, 1976·JAMA : the Journal of the American Medical Association·D D StoreyD T Coles
Dec 30, 1976·The New England Journal of Medicine·G DewaldH Gordon
Mar 11, 1975·Cancer·N MartiniE J Beattie
Jan 1, 1992·AJR. American Journal of Roentgenology·M C MorrisonP F Hahn
Apr 1, 1992·Seminars in Oncology·M J Moffett, J C Ruckdeschel
Aug 1, 1992·Current Opinion in Oncology·M Tattersall
Aug 1, 1992·American Journal of Clinical Oncology·M DavisR Barrett
Jun 1, 1992·The Western Journal of Medicine·D H Libraty
Jan 1, 1992·Chest·J E Heffner, L C Unruh
Feb 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·V W RuschS Piantadosi
Jan 1, 1990·Cancer Chemotherapy and Pharmacology·P Y HoloyeR A Newman
Sep 1, 1985·Chest·K ReshadS Hitomi
Jan 1, 1989·Journal of Surgical Oncology. Supplement·M J Ostrowski
Jun 1, 1987·Archives of Internal Medicine·D R IraniS D Greenberg
Jan 1, 1985·Medical and Pediatric Oncology·M MarkmanS B Howell
May 1, 1972·Cancer·T J CunninghamG Harrington
Jun 27, 1970·Lancet·D H Trapnell, J G Thurston
Apr 1, 1974·Cancer·C B AndersonT B Ferguson
Aug 1, 1973·The Surgical Clinics of North America·D T Carr
Nov 1, 1973·Chest·J L RatliffJ H Conn
Aug 1, 1982·American Journal of Clinical Pathology·A ToD V Coleman
Jan 1, 1983·Annals of the New York Academy of Sciences·E D RuberyR J Thompson
Jan 1, 1984·AJR. American Journal of Roentgenology·J H Woodring
Jul 1, 1994·Southern Medical Journal·P G WindsorK S Windsor
Mar 1, 1993·Seminars in Surgical Oncology·H ReichJ C Harvey
Jun 1, 1994·Chest·J E HeffnerL Unruh
Sep 1, 1993·The Annals of Thoracic Surgery·T M Daniel
Sep 1, 1993·The Annals of Thoracic Surgery·J LoCicero
Apr 1, 1993·Seminars in Nuclear Medicine·H B BreitzW B Nelp
Oct 30, 1952·The New England Journal of Medicine·R G ROSEW B STEVENS
Sep 1, 1965·Archives of Internal Medicine·L G SUHRLAND, A S WEISBERGER
Jul 27, 2005·Journal of Pain and Symptom Management·Antonio MarrazzoSebastiano Mercadante

❮ Previous
Next ❯

Citations

Jun 12, 2002·Current Treatment Options in Oncology·L B Reeder
Mar 29, 2000·The Annals of Thoracic Surgery·J B PutnamL L DeFord
Dec 11, 2002·The Surgical Clinics of North America·Joe B Putnam
Nov 20, 2009·Journal of Palliative Medicine·Vincent Thai, Ron Damant
Jun 11, 2002·Current Opinion in Pulmonary Medicine·Jeffrey S Pollak
Sep 25, 2009·Annals of Surgical Oncology·Samer BazerbashiAdrian Marchbank
Jan 20, 2006·Journal of Zhejiang University. Science. B·Shi-ping Luh, Hui-ping Liu
Aug 31, 2010·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·John E PillingPeter Goldstraw
Nov 4, 2009·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·David R JonesHeidi H Gillenwater
Mar 27, 2001·Journal of Vascular and Interventional Radiology : JVIR·J S PollakJ Murren
Aug 13, 2002·Hematology/oncology Clinics of North America·Deborah J Dudgeon
Oct 27, 2007·The Oncologist·Piergiorgio Solli, Lorenzo Spaggiari

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.